Repotrectinib
Invasive Lobular Breast Carcinoma
Explore 11 assets in Invasive Lobular Breast Carcinoma →Floatz Rating
CCC52/100
Confidence
Indicative
Sponsor
M.D. Anderson Cancer Center
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
37Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06408168CT.gov Phase II Study of REPotrectinib With or Without Fulvestrant in Patients With Hormone Receptor-positive Human Epidermal Growth Factor 2-negative Metastatic Invasive LObular Carcinoma Who Received a Prior Endocrine Therapy in Combination With Cyclin-dependent Kinase 4 and 6 Inhibitor (REPLOT Trial) | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Invasive Lobular Breast Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Repotrectinib (this asset) | M.D. Anderson Cancer Center | P2 | CCC · 52 |
| Fulvestrant | M.D. Anderson Cancer Center | P3 | BB |
| Anastrozole | Alliance for Clinical Trials in Oncology | P3 | B |
| Fes F-18 | Asan Medical Center | P2 | B |
| FAPI74 | Randy Yeh | P2 | CCC |
| Trastuzumab | Auxilio Mutuo Cancer Center | P2 | CCC |
| Epirubicin | Auxilio Mutuo Cancer Center | P2 | CCC |
| Entrectinib | Jules Bordet Institute | P2 | CCC |
| Fludeoxyglucose | Randy Yeh | P2 | CCC |
+13 more in the Invasive Lobular Breast Carcinoma cohort
Other indications for Repotrectinib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Non-Small Cell Lung Carcinoma | — | P3 | CCC · 54 |
| Hormone Receptor-Positive Breast Cancer | — | P2 | CCC · 52 |
| Metastatic Malignant Neoplasm In The Brain | — | P2 | CCC · 50 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Repotrectinib in Invasive Lobular Breast Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/repotrectinib-invasive-lobular-breast-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →